drugset / Trial / NCT07128615
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
Phase 1/2
Active not recruiting
405 enrolled
AstraZeneca
Biomedical Advanced Research and Development Authority · collabJoint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB) · collab
RandomizedSequentialQuadruple-blindPrevention
Summary
The purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes).
Timeline
- Start
- 2025-09-04
- Primary completion
- 2026-01-28
- Completion
- 2026-12-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD4117 | Unknown | — | Intramuscular |
| Subject | AZD5315 | Unknown | — | Intramuscular |